Beam Therapeutics (MEX:BEAM) Float Percentage Of Total Shares Outstanding: 64.54% (As of Jun. 30, 2026)


MEX:BEAM Beam Therapeutics Inc MEX:BEAM
66 GF Score
Price MXN628.46
GF Value MXN525.92
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Beam Therapeutics Float Percentage Of Total Shares Outstanding?

Beam Therapeutics MEX:BEAM 66 Float Percentage Of Total Shares Outstanding is 64.54% as of Jun. 30, 2026. GuruFocus rates MEX:BEAM with a GF Score™ of 66/100 and a GF Value™ of MXN525.92 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Beam Therapeutics's float shares is 66.40 Mil. Beam Therapeutics's total shares outstanding is 102.88 Mil. Beam Therapeutics's float percentage of total shares outstanding is 64.54%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Beam Therapeutics's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Beam Therapeutics's Institutional Ownership is 74.73%.

MEX:BEAM
66GF Score
Beam Therapeutics Inc MEX:BEAM
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beam Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Beam Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=66.40/102.88
=64.54%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 64.54% mean?
Beam Therapeutics (MEX:BEAM) has a Float Percentage Of Total Shares Outstanding of 64.54% as of Jun. 30, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Beam Therapeutics and its competitors.
Is Beam Therapeutics' Float Percentage Of Total Shares Outstanding too high?
Beam Therapeutics' current Float Percentage Of Total Shares Outstanding is 64.54%. Overall, Beam Therapeutics has a GF Score™ of 66/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' Float Percentage Of Total Shares Outstanding compare to ELVN and IDYA?
Beam Therapeutics' Float Percentage Of Total Shares Outstanding of 64.54% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Beam Therapeutics and its competitors. Beam Therapeutics's current Float Percentage Of Total Shares Outstanding is 64.54%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN525.92, compared to a current price of MXN628.46 — trading 19.5% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 64.54%. Beam Therapeutics' overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current Float Percentage Of Total Shares Outstanding is 64.54% as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?

Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued. The current stock price of MXN628.46 is trading 19.5% above its estimated GF Value™ of MXN525.92. GuruFocus considers Beam Therapeutics to be Modestly Overvalued.

Key valuation signals for MEX:BEAM:

  • Float Percentage Of Total Shares Outstanding: 64.54%
  • GF Value™: MXN525.92 vs. price of MXN628.46 (19.5% above fair value)
  • GF Score™: 66/100 with 6 warning signs

No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beam Therapeutics Business Description

Other Exchanges BEAM:USA
Address 238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
66GF Score

Get the complete analysis for MEX:BEAM

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN628.46
Price
MXN525.92
GF Value